tirzepatide vs semaglutide weight loss comparison caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Semaglutide vs. Tirzepatide for weight

Patients living with obesity and PCOS often present significant visceral fat accumulation, resulting in elevated free fatty acid release that contributes to increased hepatic total cholesterol synthesis and dyslipidemia, manifesting as elevated triglyceride, total cholesterol, and LDL-C levels

10.1002/mabi.202200097 [DOI] [PubMed] [Google Scholar] Man B., Hu C., Yang G., Xiang J., Yang S., Ma C

The contrasting responses to combined mTORC1 inhibition and ferroptosis induction in different cellular contexts are likely dictated by complex factors including genetic mutation landscape, the ratio of polyunsaturated to monounsaturated phospholipids, iron availability, the basal activities of the PI3K/mTORC1 pathway, and the overall cellular redox state

Kim H, et al